- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04374071
Early Short Course Corticosteroids in COVID-19
Early Short Course Corticosteroids in Hospitalized Patients With COVID-19
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Consecutive patients hospitalized between March 12, 2020 through March 27, 2020 are eligible for inclusion if they were 18 years of age or older, had confirmed COVID-19 infection, with radiographic evidence of bilateral pulmonary infiltrates, and required oxygen by nasal cannula, high-flow nasal cannula (HFNC), or mechanical ventilation. Patients are excluded if they were transferred from an out-of-system hospital, died within 24 hours of presentation to the ED, or were admitted for less than 24 hours. A confirmed case of COVID-19 was defined as a patient that had a positive reverse-transcriptase-polymerase- chain-reaction (RT-PCR) assay for SARS-CoV-2 in a nasopharyngeal sample.
Patients are risk stratified by severity of symptoms on presentation to the hospital as mild, moderate, or severe COVID-19. Patients without hypoxia or exertional dyspnea were considered to have mild COVID-19. Patients with mild COVID-19 were treated with symptom relief only and not admitted to the hospital. Patients who presented with infiltrates on chest radiography and required supplemental oxygen by nasal cannula or HFNC were classified as having moderate COVID-19. Patients who had respiratory failure requiring mechanical ventilation were classified as having severe COVID-19.
This is a multi-center quasi-experimental study at HFHS, comprised of five hospitals in southeast and south-central Michigan. The study was approved by the institution's Investigational Review Board (#13739) with waiver of consent. Patients in the pre-corticosteroid protocol group from March 12, 2020 through March 19, 2020 were compared to a corticosteroid protocol group that included patients from March 20, 2020 through March 27, 2020.
Patients in both study groups received standard care, comprised of supplemental oxygen, HFNC, invasive ventilation, antibiotic agents, antiviral agents, vasopressor support, and renal-replacement therapy, as determined by the primary team. Patients who progressed to ARDS were managed with standard of care.
Data was ascertained from each institution's electronic medical record and recorded in a standardized electronic case report form. Demographic data, information on clinical symptoms or signs at presentation, and laboratory and radiologic results during admission. All laboratory tests and radiologic assessments, including plain chest radiography and computed tomography of the chest, were performed at the discretion of the treating physician.
Coexisting conditions were ascertained from electronic medical record and physician documentation. The National Early Warning Score (NEWS) was collected to evaluate baseline illness severity based on vital signs obtained in the Emergency Department. Additionally, the quick Sequential Organ Failure Assessment (qSOFA) was used to evaluate severity of illness of included patients based on ED vitals and examination. All patients were followed for at least 14 days after initial presentation. Patient data was censored on April 9, 2020.
Statistical Analysis: Continuous variables were reported as median and interquartile range (IQR) and compared using the Mann-Whitney test or t-test, as appropriate. Categorical data was reported as number and percentage (no., %) and compared using the chi-squared test or Fisher's exact test, as appropriate. No imputation was made for missing data points. The sample size was derived from all eligible consecutive hospitalized patients during the study period. A two-sided α < 0.05 was considered statistically significant. Bivariate and multivariable logistic regression analysis was planned a-priori to test the association between the composite endpoint and exposure to the corticosteroid protocol. Covariates in the bivariate analysis with a p-value <0.2 and clinical rationale were included in a multivariable regression model that was restricted to a subject-to-variable ratio of 10:1. Statistical analysis was performed using IBM SPSS version 25 (Chicago, IL) and SAS 9.4 (Cary, NC).
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Michigan
-
Detroit, Michigan, United States, 48202
- Henry Ford Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Consecutive patients hospitalized with confirmed COVID-19 between March 12, 2020 through March 27, 2020 were eligible for inclusion.
Risk stratification by severity of symptoms on presentation: Patients without hypoxia or exertional dyspnea were considered to have mild COVID-19 and not admitted to the hospital. Patients who presented with infiltrates on chest radiography and required supplemental oxygen by nasal cannula or HFNC were classified as having moderate COVID-19. Patients who had respiratory failure requiring mechanical ventilation were classified as having severe COVID-19.
Description
Inclusion Criteria:
- 18 years of age or older
- Confirmed COVID-19 infection
- Radiographic evidence of bilateral pulmonary infiltrates
- Oxygen requirement by nasal cannula, high-flow nasal cannula (HFNC), or mechanical ventilation
Exclusion Criteria:
- Transfer from an out-of-system hospital
- Death within 24 hours of presentation to the ED
- Admitted for less than 24 hours
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Pre-Corticosteroid protocol
Patients with moderate or severe disease who presented to HFHS within the first week of the COVID epidemic in Detroit were initially treated with supportive care with or without a combination of lopinavir-ritonavir and ribavirin or hydroxychloroquine according an institutional guideline developed by Infectious Diseases Physicians and Pharmacists.
The institutional guidelines were developed by consensus, and based on the available literature, experience from Wuhan, China and other centers around the world affected by COVID-19 before Michigan.
Intravenous (IV) remdesivir compassionate use was requested for eligible mechanically ventilated patients.
On March 17, 2020 lopinavir-ritonavir with ribavirin was removed from the COVID-19 institutional protocol.
|
|
Corticosteroid Protocol
As a result of observed poor outcomes, clinical rationale based upon immunology, clinical course of COVID-19, and more recently best available evidence, the HFHS corticosteroid protocol was developed. We hypothesized that early corticosteroids would combat the inflammatory cascade leading to respiratory failure, ICU escalation of care, and mechanical ventilation. The corticosteroid protocol became the institutional standard on March 20, 2020. Patients with confirmed influenza infection were not recommended to receive corticosteroids. Patients with moderate COVID-19 who required 4 liters or more of oxygen per minute on admission, or who had escalating oxygen requirements from baseline, were recommended to receive IV methylprednisolone 0.5 to 1 mg/kg/day in 2 divided doses for 3 days. Patients who required ICU admission were recommended to receive the above regimen of hydroxychloroquine and IV methylprednisolone 0.5 to 1 mg/kg/day in 2 divided doses for 3 to 7 days. |
IV methylprednisolone 0.5 to 1 mg/kg/day in 2 divided doses for 3 days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Transfer to Intensive care unit (ICU)
Time Frame: 14 days followup for every patient in each group
|
Number of patients transferred to ICU is each of the groups
|
14 days followup for every patient in each group
|
Need for Mechanical Ventilation
Time Frame: 14 days followup for every patient in each group
|
Number of patients that needed mechanical ventilation in each of the groups
|
14 days followup for every patient in each group
|
Mortality
Time Frame: 14 days followup for every patient in each group
|
Number of patients who died in each of the groups
|
14 days followup for every patient in each group
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Development and Severity of ARDS
Time Frame: 14 days followup for every patient in each group
|
Number of patients who developed ARDS of varying severity per Berlin classification in each of the groups
|
14 days followup for every patient in each group
|
Length of hospital stay (LOS).
Time Frame: 14 days followup for every patient in each group
|
LOS in each of the groups
|
14 days followup for every patient in each group
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Mayur Ramesh, Henry Ford Health System
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Pneumonia
- Lung Diseases
- Pneumonia, Viral
- Physiological Effects of Drugs
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Neuroprotective Agents
- Protective Agents
- Prednisolone
- Methylprednisolone Acetate
- Methylprednisolone
- Methylprednisolone Hemisuccinate
- Prednisolone acetate
- Prednisolone hemisuccinate
- Prednisolone phosphate
Other Study ID Numbers
- HFH IRB # 13739
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- Study Protocol
- Statistical Analysis Plan (SAP)
- Clinical Study Report (CSR)
- Analytic Code
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pneumonia, Viral
-
Hospices Civils de LyonTerminatedCOVID-19 | Viral Pneumonia Human CoronavirusFrance
-
University of Texas Southwestern Medical CenterWithdrawnBacterial Pneumonia | Viral PneumoniaUnited States
-
Cairo UniversityUnknown
-
Zhong WangNot yet recruiting
-
Wecare Probiotics Co., Ltd.Not yet recruitingViral Pneumonia
-
Instituto Nacional de Ciencias Medicas y Nutricion...CompletedCoronavirus Infections | COVID-19 | Viral Pneumonia Human CoronavirusMexico
-
Francesco De CobelliCompleted
-
South Egypt Cancer InstituteRecruiting
-
University Hospital, LilleCompleted
-
Assistance Publique Hopitaux De MarseilleCompleted
Clinical Trials on Methylprednisolone
-
Rennes University HospitalUnknownMultiple Sclerosis, Relapsing-RemittingFrance
-
Assistance Publique - Hôpitaux de ParisCompleted
-
Chang Gung Memorial HospitalRecruitingMucocutaneous Lymph Node SyndromeTaiwan
-
Fred LublinPfizer; National Multiple Sclerosis SocietyTerminatedMultiple SclerosisUnited States
-
Universidad Nacional Autonoma de MexicoInstituto Nacional de Neurología y NeurocirugíaEnrolling by invitationMethylprednisolone | Intranasal Administration | Patients With an Active Multiple Sclerosis RelapseMexico
-
LEO PharmaBayerCompleted
-
Assiut UniversityCompleted
-
University of Colorado, DenverUniversity of Pennsylvania; MallinckrodtTerminatedMultiple SclerosisUnited States
-
Fundação de Medicina Tropical Dr. Heitor Vieira...CompletedSARS-CoV Infection | Severe Acute Respiratory Syndrome (SARS) PneumoniaBrazil
-
Peking University People's HospitalBeijing HospitalUnknownImmune Thrombocytopenia